Developing assays to address identity, potency, purity and safety: Cell characterization in cell therapy process development

Regenerative Medicine

Volumn 7, Issue 1, 2012, Pages 85-100

  Carmen, Jessica ^a   Burger, Scott R ^b   McCaman, Michael ^a   Rowley, Jon A ^a  

^a Cell Therapy Research and Development   (United States)

^b Advanced Cell and Gene Therapy   (United States)

Author keywords

assay; cell characterization; cell therapy; cell based therapy; cellular therapy; identity; potency; process development; regenerative medicine

Indexed keywords

BIOLOGICAL MARKER;

AUTOLOGOUS STEM CELL TRANSPLANTATION; BIOLOGICAL ACTIVITY; CELL ASSAY; CELL DIFFERENTIATION; CELL ISOLATION; CELL THERAPY; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; HUMAN; MESENCHYMAL STEM CELL; NONHUMAN; PATIENT SAFETY; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROCESS OPTIMIZATION; PROTEIN EXPRESSION; PURIFICATION; REGENERATIVE MEDICINE; REVIEW; SEPARATION TECHNIQUE; TOTAL QUALITY MANAGEMENT;

BIOLOGICAL ASSAY; HUMANS; QUALITY CONTROL; TISSUE THERAPY;

EID: 83655212715     PISSN: 17460751     EISSN: 1746076X     Source Type: Journal    
DOI: 10.2217/rme.11.105     Document Type: Review

References (50)

1. Mason C, Dunnill P. Translational regenerative medicine research: essential to discovery and outcome. Regen. Med. 2(3), 227-229 (2007). (Pubitemid 46845883)
2. James D. Therapies of tomorrow require more than factories from the past. Bioproc. Int. 9, 4-11 (2011).
3. Mason C, Hoare M. Regenerative medicine bioprocessing: the need to learn from the experience of other fields. Regen. Med. 1(5), 615-623 (2006).
4. Bravery C. Regulating interface science healthcare products: myths and uncertainties. J. R. Soc. Interface 7, 7 (2010).
5. Brandenberger R, Burger S, Campbell A, Fong T, Lapinskas E, Rowley J. Cell therapy bioprocessing integrating process and product development for the next generation of biotherapeutics. Bioproc. Int. 9(Suppl. 1), 30-37 (2011).
6. Regenerative medicine glossary. Regen. Med. 4(Suppl. 4), S1-S88 (2009).
7. Rayment EA, Williams DJ. Concise review. Mind the gap: challenges in characterizing and quantifying cell- and tissue-based therapies for clinical translation. Stem Cells 28(5), 996-1004 (2010).
8. US FDA. Guidance for FDA Reviewers and Sponsors. Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Somatic Cell Therapy Investigational New Drug Applications (INDs). US Department of Health and Human Services, Rockville, MD, USA, 1, 1-39 (2008).
9. FDA summary for basis of approval: BLA Ref No. 96-0372, Carticel.
10. Mcintyre C, Flyg B, Fong T. Fluorescence-activated cell sorting for CGMP processing of therapeutic cells. Bioproc. Int. 8, 44-53 (2010).
11. Suni MA, Dunn HS, Orr PL et al. Performance of plate-based cytokine flow cytometry with automated data analysis. BMC Immunol. 4, 9 (2003).
12. Stroncek DF, Jin P, Wang E, Ren J, Sabatino M, Marincola FM. Global transcriptional analysis for biomarker discovery and validation in cellular therapies. Mol. Diagn. Ther. 13(3), 181-193 (2009).
13. Kim KS, Kim JS, Lee MR, Jeong HS, Kim J. A study of microRNAs in silico and in vivo: emerging regulators of embryonic stem cells. FEBS J. 276(8), 2140-2149 (2009).
14. D'amour KA, Agulnick AD, Eliazer S, Kelly OG, Kroon E, Baetge EE. Efficient differentiation of human embryonic stem cells to definitive endoderm. Nat. Biotechnol. 23(12), 1534-1541 (2005). (Pubitemid 41752931)
15. Caplan AI. Why are MSCs therapeutic? New data: new insight. J. Pathol. 217(2), 318-324 (2009).
16. Wang M, Crisostomo PR, Herring C, Meldrum KK, Meldrum DR. Human progenitor cells from bone marrow or adipose tissue produce VEGF, HGF, and IGF I in response to TNF by a p38 MAPK-dependent mechanism. Am. J. Physiol. Regul. Integr. Comp. Physiol. 291(4), R880-R884 (2006). (Pubitemid 44498426)
17. US FDA. Final Guidance for Industry. Potency Tests for Cellular and Gene Therapy Products. US Department of Health and Human Services, Rockville, MD, USA, 1, 1-19 (2011).
18. Liu CH, Hwang SM. Cytokine interactions in mesenchymal stem cells from cord blood. Cytokine 32(6), 270-279 (2005).
19. Yagi H, Soto-Gutierrez A, Parekkadan B et al. Mesenchymal stem cells: mechanisms of immunomodulation and homing. Cell Transplant. 19(6), 667-679 (2010).
20. Curti A, Trabanelli S, Salvestrini V, Baccarani M, Lemoli RM. The role of indoleamine 2,3 dioxygenase in the induction of immune tolerance: focus on hematology. Blood 113(11), 2394-2401 (2009).
21. Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8(4), 315-317 (2006). (Pubitemid 44269669)
22. + cytotoxic T cell responses in vitro. J. Immunother. 34(1), 45-57 (2011).
23. Kasten P, Beyen I, Egermann M et al. Instant stem cell therapy: characterization and concentration of human mesenchymal stem cells in vitro. Eur. Cell. Mater. 16, 47-55 (2008).
24. + cells and CFU-GM with time to hematopoietic engraftment. Bone Marrow Transplant. 35(9), 881-887 (2005). (Pubitemid 40667630)
25. Goltry K, Rowley J, Peters M, Burchardt E. Tissue repair cells for the treatment of cardiovascular diseases. Adv. Mol. Med. 3(1), 9 (2007).
26. Rich IN, Hall KM. Validation and development of a predictive paradigm for hemotoxicology using a multifunctional bioluminescence colony forming proliferation assay. Toxicol. Sci. 87(2), 427-441 (2005). (Pubitemid 41300690)
27. Zhang YW, Denham J, Thies RS. Oligodendrocyte progenitor cells derived from human embryonic stem cells express neurotrophic factors. Stem Cells Dev. 15(6), 943-952 (2006). (Pubitemid 46147864)
28. Kroon E, Martinson LA, Kadoya K et al. Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat. Biotechnol. 26(4), 443-452 (2008). (Pubitemid 351501814)
29. Klimanskaya I, Hipp J, Rezai KA, West M, Atala A, Lanza R. Derivation and comparative assessment of retinal pigment epithelium from human embryonic stem cells using transcriptomics. Cloning Stem Cells 6(3), 217-245 (2004). (Pubitemid 39391307)
30. Ellington AA, Kullo IJ, Bailey KR, Klee GG. Antibody-based protein multiplex platforms: technical and operational challenges. Clin. Chem. 56(2), 186-193 (2009).
31. Goldring CE, Duffy PA, Benvenisty N et al. Assessing the safety of stem cell therapeutics. Cell Stem Cell 8(6), 618-628 (2011).
32. Nelson PN, Carnegie PR, Martin J et al. Demystified. Human endogenous retroviruses. Mol. Pathol. 56(1), 11-18 (2003).
33. Ryan FP. Human endogenous retroviruses in health and disease: a symbiotic perspective. J. R. Soc. Med. 97(12), 560-565 (2004). (Pubitemid 39656944)
34. International Conference on Harmonisation. Q5A Viral Safety Evaluation of Biotechnology Products Derived From Cell Lines of Human or Animal Origin. EMEA, Canary Wharf, London, UK, 1, 1-33 (2006).
35. Morgan RA, Dudley ME, Rosenberg SA. Adoptive cell therapy: genetic modification to redirect effector cell specificity. Cancer J. 16(4), 336-341 (2010).
36. US FDA. Guidance for Industry. Guidance for Human Somatic Cell Therapy and Gene Therapy. US Department of Health and Human Services, Rockville, MD, USA, 1, 30 (1998).
37. Higano CS, Small EJ, Schellhammer P et al. Sipuleucel T. Nature Rev. Drug Discov. 9(7), 513-514 (2010).
38. Carpenter MK, Frey-Vasconcells J, Rao MS. Developing safe therapies from human pluripotent stem cells. Nat. Biotechnol. 27(7), 606-613 (2009).
39. Strauss S. Geron trial resumes, but standards for stem cell trials remain elusive. Nat. Biotechnol. 28(10), 989-990 (2010).
40. Sun X, Long X, Yin Y et al. Similar biological characteristics of human embryonic stem cell lines with normal and abnormal karyotypes. Hum. Reprod. 23(10), 2185-2193 (2008).
41. Gore A, Li Z, Fung HL et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 471(7336), 63-67 (2011).
42. US FDA. Guidance for Industry. Process Validation: General Principles and Practices. US Department of Health and Human Services, Rockville, MD, USA, 1, 1-22 (2011).
43. International Conference on Harmonisation. Q5E. Comparability of Biotechnological/ Biological Products Subject to Changes in Their Manufacturing Process. EMEA, Canary Wharf, London, UK, 1, 1-11 (2003).
44. International Conference on Harmonisation. Q5C. Guideline for Industry: Quality of Biotechnological Products: Stability Testing of Biotechnological/ Biological Products. EMEA, Canary Wharf, London, UK, 1, 1-12 (1996).
45. Thomas RJ, Hourd PC, Williams DJ. Application of process quality engineering techniques to improve the understanding of the in vitro processing of stem cells for therapeutic use. J. Biotechnol. 136(3-4), 148-155 (2008).
46. Julien C, Whitford W. The biopharmaceutical industry's new operating paradigm. Bioproc. Int. 8, 6-14 (2008).
47. Rowley J. Developing cell biomanufacturing processes. Chem. Eng. Prog. SBE(Suppl.), 6 (2010).
48. Fensten R. Understanding Animal Sera: Considerations for Use in the Production of Biological Therapeutics. John Wiley and Sons Ltd, West Sussex, UK, 45-58 (2007).
49. Dahl JA, Duggal S, Coulston N et al. Genetic and epigenetic instability of human bone marrow mesenchymal stem cells expanded in autologous serum or fetal bovine serum. Int. J. Dev. Biol. 52(8), 1033-1042 (2008).
50. Shahdadfar A, Fronsdal K, Haug T, Reinholt FP, Brinchmann JE. In vitro expansion of human mesenchymal stem cells: choice of serum is a determinant of cell proliferation, differentiation, gene expression, and transcriptome stability. Stem Cells 23(9), 1357-1366 (2005). (Pubitemid 41504923)